Credit Suisse Ag Mersana Therapeutics, Inc. Transaction History

Credit Suisse Ag

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.06 - $3.91 $20,559 - $75,838	-19,396 Reduced 13.06%	129,067 $163,000
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $137,318 - $425,777	44,584 Added 42.92%	148,463 $488,000
Q1 2023 May 10, 2023	BUY	$4.0 - $7.02 $25,620 - $44,963	6,405 Added 6.57%	103,879 $426,000
Q4 2022 Feb 13, 2023	SELL	$5.65 - $7.86 $29,340 - $40,816	-5,193 Reduced 5.06%	97,474 $571,000
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $102,438 - $177,000	22,125 Added 27.47%	102,667 $693,000
Q2 2022 Aug 12, 2022	BUY	$2.84 - $5.0 $13,021 - $22,925	4,585 Added 6.04%	80,542 $373,000
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $34,542 - $61,234	9,236 Added 13.84%	75,957 $304,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $80,145 - $144,202	14,625 Added 28.07%	66,721 $415,000
Q3 2021 Nov 12, 2021	SELL	$8.56 - $14.47 $17,642 - $29,822	-2,061 Reduced 3.81%	52,096 $492,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $9,495 - $12,920	715 Added 1.34%	54,157 $736,000
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $915,507 - $1.59 Million	-59,798 Reduced 52.81%	53,442 $863,000
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $8,369 - $13,712	497 Added 0.44%	113,240 $3.01 Million
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $890,530 - $1.41 Million	54,971 Added 95.15%	112,743 $2.1 Million
Q2 2020 Aug 12, 2020	BUY	$5.24 - $23.4 $302,725 - $1.35 Million	57,772 New	57,772 $1.35 Million
Q4 2019 Feb 12, 2020	SELL	$1.45 - $6.73 $15,758 - $73,141	-10,868 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$1.54 - $4.2 $16,736 - $45,645	10,868 New	10,868 $17,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $192M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.